Premium
Endobronchial photodynamic therapy for lung cancer
Author(s) -
Loewen Gregory M.,
Pandey Ravindra,
Bellnier David,
Henderson Barbara,
Dougherty Thomas
Publication year - 2006
Publication title -
lasers in surgery and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.888
H-Index - 112
eISSN - 1096-9101
pISSN - 0196-8092
DOI - 10.1002/lsm.20354
Subject(s) - photodynamic therapy , medicine , lung cancer , photosensitivity , photosensitizer , carcinoma , lung , cancer , dermatology , surgery , pathology , quantum mechanics , chemistry , physics , organic chemistry
Background and Objective Endobronchial photodynamic therapy (PDT) is a minimally invasive technique for the palliation of major airway obstruction from lung cancer, and for the treatment of endobronchial microinvasive lung cancer. Study Design Results of reported clinical trials were compared, and the author's preliminary results with second generation photosensitizers were also reviewed. Results A review of the clinical experience with endobronchial PDT is provided. Potential advantages of PDT include the duration of palliation achieved through the delayed cellular effects of PDT within tumor. Side‐effects from FDA‐approved photosensitizer (Photofrin, Porfimer sodium, Axcan Scandipharm, Montreal, Quebec) include skin photosensitivity. HPPH (2‐[1‐hexyloxyethyl]‐2 devinyl pyropheophorbide) is an example of a second‐generation photosensitize that shows promise in the treatment of lung cancer, and appears to be free from significant skin photosensitivity. Conclusion PDT is an effective tool for the palliation of endobronchial lung cancers which obstruct the central airways and is also effective for the treatment of central microinvasive carcinoma and carcinoma in situ of the central airways. Lasers Surg. Med. 38:364–370, 2006. © 2006 Wiley‐Liss, Inc.